National Estimates of the Adult Diabetes Care Continuum in India, 2019-2021.
Journal
JAMA internal medicine
ISSN: 2168-6114
Titre abrégé: JAMA Intern Med
Pays: United States
ID NLM: 101589534
Informations de publication
Date de publication:
31 Jul 2023
31 Jul 2023
Historique:
pmc-release:
31
07
2024
medline:
31
7
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
aheadofprint
Résumé
Diabetes is widespread and treatable, but little is known about the diabetes care continuum (diagnosis, treatment, and control) in India and how it varies at the national, state, and district levels. To estimate the adult population levels of diabetes diagnosis, treatment, and control in India at national, state, and district levels and by sociodemographic characteristics. In this cross-sectional, nationally representative survey study from 2019 to 2021, adults in India from 28 states, 8 union territories, and 707 districts were surveyed for India's Fifth National Family Health Survey (NFHS-5). The survey team collected data on blood glucose among all adults (18-98 years) who were living in the same household as eligible participants (pregnant or nonpregnant female individuals aged 15-49 years and male individuals aged 15-54 years). The overall sample consisted of 1 895 287 adults. The analytic sample was restricted to those who either self-reported having diabetes or who had a valid measurement of blood glucose. The exposures in this survey study were district and state residence; urban vs rural residence; age (18-39 years, 40-64 years, or ≥65 years); sex; and household wealth quintile. Diabetes was defined by self-report or high capillary blood glucose (fasting: ≥126 mg/dL [to convert to mmol/L, multiply by 0.0555]; nonfasting: ≥220 mg/dL). Among respondents who had previously been diagnosed with diabetes, the main outcome was the proportion treated based on self-reported medication use and the proportion controlled (fasting: blood glucose <126 mg/dL; nonfasting: ≤180 mg/dL). The findings were benchmarked against the World Health Organization (WHO) Global Diabetes Compact targets (80% diagnosis; 80% control among those diagnosed). The variance in indicators between and within states was partitioned using variance partition coefficients (VPCs). Among 1 651 176 adult respondents (mean [SD] age, 41.6 [16.4] years; 867 896 [52.6%] female) with blood glucose measures, the proportion of individuals with diabetes was 6.5% (95% CI, 6.4%-6.6%). Among adults with diabetes, 74.2% (95% CI, 73.3%-75.0%) were diagnosed. Among those diagnosed, 59.4% (95% CI, 58.1%-60.6%) reported taking medication, and 65.5% (95% CI, 64.5%-66.4%) achieved control. Diagnosis and treatment were higher in urban areas, older age groups, and wealthier households. Among those diagnosed in the 707 districts surveyed, 246 (34.8%) districts met the WHO diagnosis target, while 76 (10.7%) districts met the WHO control target. Most of the variability in diabetes diagnosis (VPC, 89.1%), treatment (VPC, 85.9%), and control (VPC, 95.6%) were within states, not between states. In this survey study, the diabetes care continuum in India is represented by considerable district-level variation, age-related disparities, and rural-urban differences. Surveillance at the district level can guide state health administrators to prioritize interventions and monitor achievement of global targets.
Identifiants
pubmed: 37523192
pii: 2807945
doi: 10.1001/jamainternmed.2023.3070
pmc: PMC10391358
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Lancet Diabetes Endocrinol. 2022 Jun;10(6):430-441
pubmed: 35461575
BMC Public Health. 2016 Aug 18;16(1):816
pubmed: 27538686
Diabetes Care. 2023 Jan 1;46(Supple 1):S10-S18
pubmed: 36507639
Lancet. 2023 Apr 15;401(10384):1302-1312
pubmed: 36931289
Diabetes Technol Ther. 2014 Sep;16(9):596-603
pubmed: 25101698
JAMA Intern Med. 2018 Mar 1;178(3):363-372
pubmed: 29379964
Int J Epidemiol. 2022 Aug 10;51(4):e167-e176
pubmed: 35021187
J Diabetes Sci Technol. 2015 Oct 09;10(2):350-65
pubmed: 26452633
Ann Intern Med. 2014 Nov 18;161(10):681-9
pubmed: 25402511
J Diabetes. 2016 Nov;8(6):766-769
pubmed: 27400903
Int J Behav Nutr Phys Act. 2014 Feb 26;11(1):26
pubmed: 24571915
Sci Transl Med. 2022 Jul 6;14(652):eabi9522
pubmed: 35857627
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):45-53
pubmed: 33310176
BMC Med. 2019 May 13;17(1):92
pubmed: 31084606
Lancet Healthy Longev. 2021 Jun;2(6):e340-e351
pubmed: 35211689
Lancet Glob Health. 2020 Sep;8(9):e1142-e1151
pubmed: 32682459
Diabetes Care. 2013 Sep;36(9):2628-38
pubmed: 23628621
Clin Chem Lab Med. 2006;44(11):1376-8
pubmed: 17087653
Diabetes Care. 2006 Sep;29(9):2130-6
pubmed: 16936167
Ann Neurosci. 2020 Jul;27(3-4):193-203
pubmed: 34556960
Front Public Health. 2022 Mar 14;10:748157
pubmed: 35359772
J R Soc Interface. 2017 Sep;14(134):
pubmed: 28904005
Lancet Diabetes Endocrinol. 2017 Aug;5(8):585-596
pubmed: 28601585
Diabetes Care. 2020 Jul;43(7):1557-1592
pubmed: 33534729